US 12,245,754 B2
Pharmaceutical composition for treating influenza virus infections
Syou Okiyama, Tokyo (JP)
Assigned to AILLIS INC., (JP)
Appl. No. 17/623,376
Filed by AILLIS INC., Tokyo (JP)
PCT Filed Jun. 30, 2020, PCT No. PCT/JP2020/025652
§ 371(c)(1), (2) Date Dec. 28, 2021,
PCT Pub. No. WO2021/002355, PCT Pub. Date Jan. 7, 2021.
Claims priority of application No. 2019-124750 (JP), filed on Jul. 3, 2019.
Prior Publication US 2022/0361741 A1, Nov. 17, 2022
Int. Cl. A61B 1/24 (2006.01); A61K 31/196 (2006.01); A61K 31/215 (2006.01); A61K 31/351 (2006.01); A61K 31/5383 (2006.01); G06T 7/00 (2017.01)
CPC A61B 1/24 (2013.01) [A61K 31/196 (2013.01); A61K 31/215 (2013.01); A61K 31/351 (2013.01); A61K 31/5383 (2013.01); G06T 7/0012 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A pharmaceutical composition for treating an influenza virus infectious disease, comprising an anti-influenza virus agent as an active ingredient,
wherein the anti-influenza virus agent is administered to a patient determined to be positive for the influenza virus infectious disease based on an intraoral image captured using an intraoral imaging apparatus.